Catalog No.
Product Name
Application
Product Information
Citations
-
HIV Inhibitor
HIV-1 inhibitor-36 is a potent inhibitor targeting HIV-1, exhibiting significant antiviral activity against the virus. It has potential applications in the development of novel latency-reversing agents, making it a valuable tool for research in HIV treatment and eradication strategies. This compound may facilitate the understanding of viral latency and aid in the advancement of therapeutic approaches to HIV infection. -
HIV-1 Reverse Transcriptase Inhibitor
HI-236 is a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase, effectively disrupting the replication of the HIV virus. It demonstrates exceptional antiviral activity, with an IC50 value of less than 0.001 μM against wild-type HTLVIIIB. This compound is primarily utilized in HIV research, particularly in the development of antiretroviral therapies. -
HIV Inhibitor
F1839-I is an HIV inhibitor derived from the fungus Stachybotrys. It exhibits anti-HIV activity with an IC50 value of 15.6 μM, demonstrating its potential in therapeutic applications against HIV infection. Additionally, F1839-I has shown weak cytotoxicity, supporting its feasibility for further research in antiviral drug development. -
HIV-1 Nef Binder, Calnexin Binder
NSC 13987 is a selective inhibitor of the HIV-1 Nef protein, specifically targeting site I. By binding to Nef, NSC 13987 disrupts its interaction with calnexin, leading to the restoration of cholesterol efflux that is typically inhibited by Nef. This compound is valuable for research into HIV-associated atherosclerosis, providing insights into the mechanisms behind HIV infection and its impact on lipid metabolism. -
HIV-1 Inhibitor
VIRIP, derived from human α1-AT(353-372), functions as an inhibitor of HIV-1 by targeting the gp41 fusion peptide. It prevents the entry of HIV-1 into host cells, thereby disrupting the viral lifecycle. This reagent is applicable in virology research and studies focused on HIV-1 entry mechanisms. -
HIV-1 Inhibitor
Kadsuracoccinic acid A is a tetracyclic natural compound targeting HIV-1. It exhibits significant anti-HIV-1 activity in vitro, with an EC50 value of 68.7 μM. This compound is valuable for research in the development of antiviral therapies and understanding HIV-1 inhibition mechanisms. -
CCR5 Antagonist
Ancriviroc is a small molecule CCR5 antagonist that demonstrates potent antiviral activity against various HIV-1 isolates that utilize CCR5 as an entry coreceptor, with IC50 values ranging from 0.4 to 9 nM. This compound effectively inhibits the replication of R5-utilizing HIV-1 strains in the SCID-hu Thy/Liv mice model of HIV-1 infection. Ancriviroc is a valuable tool for research focused on HIV infection and the exploration of therapeutic strategies targeting CCR5. -
HIV Inhibitor
HIV-1 inhibitor-70 is a bifunctional inhibitor targeting both wild-type and K103N mutant reverse transcriptases of HIV-1. This compound effectively disrupts the replication of the virus, making it valuable in HIV research and therapeutic investigations. Its dual inhibitory action provides insights into resistance mechanisms and aids in the development of effective treatments for HIV infections. -
HIV protease inhibitor
SB 204144 is a potent inhibitor of HIV protease, disrupting the proteolytic processing of viral polyproteins and hindering the maturation of infectious HIV particles. This compound is valuable for research on HIV pathogenesis and immune system diseases, enabling studies on antiviral effects and the development of new therapeutic strategies against HIV. Its application in virology underlines its relevance in understanding and combating HIV infection. -
HIV Inhibitor
B07 is a potent HIV inhibitor that targets viral replication mechanisms. In addition to its antiviral properties, B07 also exhibits spermicidal activity with an EC50 of 1.5 mg/mL. This compound has valuable applications in HIV research and the development of contraceptive agents. -
CCR5 Antagonist
INCB9471 is a potent and selective CCR5 antagonist that serves as a critical resource for HIV-1 research. This orally active compound effectively inhibits CCR5-mediated entry of HIV-1 into host cells, demonstrating significant anti-HIV-1 activity. Its targeted mechanism of action makes INCB9471 a valuable tool for studying HIV pathogenesis and developing therapeutic strategies against HIV infection. -
HIV-1 Inhibitor
GS-9822 is a potent HIV-1 inhibitor that specifically targets the LEDGF/p75-integrase interaction, demonstrating robust antiviral activity with an IC50 of 0.07 μM against wild-type HIV-1 viruses. It exhibits high in vitro metabolic stability and favorable oral pharmacokinetic properties, characterized by low systemic clearance across various preclinical animal models, including rats, dogs, and monkeys. GS-9822 is a valuable tool for research applications focused on understanding HIV-1 integration and developing therapeutic strategies against viral infections. -
HIV-1 Inhibitor
Fosamprenavir-d4 is a deuterium-labeled inhibitor targeting HIV-1 protease. As a prodrug of Amprenavir, Fosamprenavir is hydrolyzed by cell phosphatases, converting it into Amprenavir, which subsequently binds to the active site of HIV-1 protease. This binding prevents the processing of essential viral precursors, inhibiting the production of mature and infectious virions. Fosamprenavir-d4 is useful for research focused on HIV-1 infection and therapeutic strategies against the virus. -
HIV Inhibitor
Tsugafolin is a dehydroflavone that acts as an inhibitor of HIV. It exhibits weak anti-HIV activity with an IC50 value of 118 μM while demonstrating low cytotoxicity at concentrations below 150 μM. Isolated from the plant Vitex leptobotrys, Tsugafolin serves as a valuable tool for research applications focused on HIV-1 replication and the development of therapeutic strategies. -
HIV
(S)-BMS-378806 is a potent HIV-1 inhibitor that primarily targets the gp120-CD4 interaction, disrupting the crucial binding necessary for viral entry into host cells. This compound demonstrates micromolar inhibition of HIV-1 gp120-CD4 binding, making it a valuable tool for understanding HIV pathogenesis and developing therapeutic strategies. The design of (S)-BMS-378806 was informed by detailed studies of protein-ligand interactions, leading to the synthesis of innovative symmetrical N,N'-disubstituted aminoureas and thioureas. Its inhibitory activity has been confirmed through HIV-1 gp120-CD4 capture ELISA. -
HIV-l Encoded Protease Inhibitor
L-738872 is a potent orally active inhibitor of the HIV-1 encoded protease. It effectively inhibits viral replication by interfering with the processing of viral polyproteins, which is critical for the maturation of infectious HIV particles. This compound is valuable in research focused on understanding HIV protease functionality and developing antiretroviral therapies. -
HIV-1 Reverse Transcriptase Inhibitor
Urushiol (15:3) is an inhibitor of HIV-1 reverse transcriptase, demonstrating moderate inhibitory activity with an IC50 value of 55.36 μM. This compound, derived from the leaves of Rhus verniciflua, exhibits significant cytotoxicity against prostate cancer PC-3 cells and normal MRC-5 cells. Urushiol (15:3) is relevant for research into anti-HIV-1 therapies and the study of prostate cancer biology. -
CCR5 Antagonist
Vicriviroc is a potent CCR5 antagonist with an IC50 of 10 nM. It effectively inhibits the release of MIP-1α and intracellular calcium levels induced by the ligand RANTES, with IC50 values of 0.91 nM and 16 nM, respectively. Vicriviroc is primarily utilized in research related to human immunodeficiency virus type 1 (HIV-1) infection and holds potential for cancer studies. -
HIV NNRT Inhibitor
BI-2540 is a potent non-nucleoside reverse transcriptase (NNRT) inhibitor targeting HIV. This compound exhibits significant antiviral activity by inhibiting the reverse transcription process, thereby preventing viral replication. BI-2540 is utilized in research for the development of therapeutic strategies against HIV and contributes to the understanding of HIV resistance mechanisms. -
HIV-1 RT Inhibitor
L 738372 is a non-competitive reversible inhibitor of HIV-1 reverse transcriptase (RT) with a reported inhibition constant (Ki) of 140 nM against dTTP. This compound demonstrates synergistic inhibition of RT activity when used in combination with nucleoside analogs such as azidothymidine triphosphate, didexoyinosine triphosphate, or didexoycytidine triphosphate. Notably, L 738372 exhibits enhanced inhibitory potency against azidothymidine-resistant RT variants (D67N, K70R, T215Y, K219Q), making it a valuable tool for advancing research in HIV treatment strategies. -
Reverse Transcriptase
Etravirine-d4 is a deuterium-labeled analog of Etravirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) targeting HIV reverse transcriptase. This compound is utilized in research to study the mechanisms of HIV inhibition and resistance. Etravirine-d4 is particularly valuable for pharmacokinetic studies and metabolic profiling in antiviral research. -
HIV Inhibitor
H-Gly-Pro-Gly-NH2 is a tripeptide that serves as an inhibitor of HIV-1 and HIV-2 replication. Demonstrating EC50 values of 35 µM for HIV-1 IIIB and 30 µM for HIV-2 ROD, H-Gly-Pro-Gly-NH2 reduces viral replication by disrupting capsid formation in vitro. This compound possesses significant antiviral activity, making it a valuable tool for research into HIV and related viral mechanisms. -
HIV
GPI2A is a 20-mer antisense oligonucleotide targeting the HIV-1 gag gene. This compound demonstrates significant inhibition of the viral proteins p55 and its cleavage products p39/41, making it a valuable tool for HIV research. GPI2A may be used to study the mechanisms of HIV replication and the potential for therapeutic intervention in HIV-1 infections. -
HIV-1 Inhibitor
GSK3532795 oxalate is a potent second-generation inhibitor of HIV-1 maturation, acting primarily through the disruption of viral particle assembly. It exhibits notable efficacy with EC50 values of 1.9 nM for HIV-1 wild type, 10.2 nM in human serum, as well as 2.7 nM and 13 nM for the HIV-1 V370A and ΔV370 variants, respectively. This compound is essential for research focused on HIV-1 infection mechanisms and therapeutic strategies. -
Non-nucleoside Reverse Transcriptase Inhibitor
Capravirine is an orally active non-nucleoside reverse transcriptase inhibitor (NNRTI) primarily targeting the HIV-1 reverse transcriptase enzyme. It demonstrates potent antiviral activity against various strains of HIV-1, including those resistant to both nucleoside/nucleotide reverse transcriptase inhibitors and other NNRTIs. Capravirine is metabolized by the cytochrome P450 enzyme CYP3A4, making it relevant for studies on drug interactions and resistance mechanisms in HIV research. -
HIV-1 Inhibitor
HIV-1 inhibitor-34 is a potent and selective inhibitor of HIV-1, exhibiting an EC50 value of 6.4 nM in HIV-1 assays and a CC50 of 16 μM in MT-4 cells. This compound is valuable for research applications focused on understanding HIV-1 replication and pathogenesis, making it a useful tool for studies related to AIDS therapeutics. -
HIV Inhibitor
SJ-3366 is a potent inhibitor of HIV non-nucleoside reverse transcriptase. This compound demonstrates significant inhibitory activity at sub-nanomolar concentrations, functioning through a typical non-nucleoside mechanism. SJ-3366 is utilized in research applications focused on HIV replication and the development of antiretroviral therapies. -
HIV Inhibitor Prodrug
HIV-IN-13 prodrug is designed as a prodrug of an HIV inhibitor, engaging specifically with viral components upon conversion. In the presence of glutathione (GSH), this compound exhibits significant antiviral activity, demonstrating EC50 values of 10 μM and 8.2 μM against HIV-1 at concentrations of 1 mM and 2 mM GSH, respectively. This prodrug serves as a valuable tool for research focused on HIV infection and therapeutic development. -
HIV Substrate
Fluorescent HIV Substrate is specifically designed to facilitate the study of HIV protease activity. This highly sensitive substrate emits fluorescence upon cleavage by the HIV protease, enabling real-time monitoring of enzymatic activity. It serves as an essential tool in HIV research, helping to evaluate protease inhibitors and advance therapeutic strategies against HIV infection. -
HIV-1 Inhibitor
NB-64 is an orally active inhibitor of HIV-1 that targets viral replication. Its significant antiviral activity makes it a valuable tool for research into HIV infections and the development of therapeutic strategies. This compound contributes to a better understanding of HIV pathogenesis and potential treatment options. -
HIV Inhibitor
PNU-142721 is a reverse transcriptase inhibitor that targets HIV by effectively inhibiting various type I variants. This compound serves as a valuable tool in HIV research, particularly in the study of viral replication and resistance mechanisms. Its dual function as a PXR agonist further enhances its relevance in investigating drug metabolism and therapeutic strategies against HIV. -
HIV Integrase Inhibitor
Lepetegravir is a potent HIV integrase inhibitor that exerts its antiviral effects by blocking the integration of viral DNA into the host genome. With an EC50 value of 0.98 nM in MT-4 cells, it demonstrates strong efficacy in suppressing HIV replication. Lepetegravir is applicable in research aimed at understanding HIV pathogenesis and developing antiretroviral therapies. -
Anti-HIV Agent
NYAD-13 is an anti-HIV agent that demonstrates antiviral activity against HIV-1 IIIB. While it shows potential in inhibiting viral replication, it is important to note that it also exhibits significant cytotoxicity. This compound may be useful in research focused on understanding the mechanisms of HIV infection and evaluating antiviral strategies. -
HIV-1 Integrase Inhibitor
Integracin B is a potent inhibitor targeting HIV-1 integrase through a dimeric alkyl aromatic structure. It effectively inhibits both the coupled and strand transfer activities of the integrase, making it a valuable tool for studying HIV-1 replication and integration processes. This compound is suitable for research applications focused on antiviral drug development and the mechanistic understanding of integrase-mediated viral entry. -
Control of Anti-HIV Agent
Marsdenoside F is a polyoxygenated pregnane glycoside derived from the stems of Marsdenia tenacissima, primarily targeting anti-HIV applications. In biological assays, Marsdenoside F demonstrated negligible cytotoxicity toward A549 and MCF-7 cell lines, as well as a lack of significant anti-HIV activity. Its properties make it a candidate for further research in the context of HIV treatment and cell line studies. -
HIV Inhibitor
HIV-1 Inhibitor-9 is a potent inhibitor targeting HIV-1, effectively inhibiting both wild-type and various non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant strains at low nanomolar concentrations. This compound demonstrates significant antiviral activity, making it a valuable tool for research into HIV treatment and drug resistance mechanisms. Its efficacy against resistant strains supports its potential use in therapeutic studies and drug development efforts aimed at combating HIV-1 infection. -
Reverse Transcriptase Inhibitor
Inophyllum B is a potent inhibitor of HIV reverse transcriptase, exhibiting an impressive IC50 value of 38 nM. This compound effectively inhibits HIV-1 in vitro cell cultures with an IC50 of 1.4 μM. Inophyllum B is isolated from the acetone extract of the giant African snail, Achatina fulica, making it a valuable reagent for research applications focused on antiviral drug development and the mechanisms of HIV replication. -
HIV Inhibitor
Tripterifordin is a potent inhibitor of HIV replication, specifically targeting H9 lymphocyte cells. It demonstrates significant anti-HIV activity with an EC50 value of 3100 nM. This compound is valuable for research applications aimed at understanding HIV pathogenesis and developing therapeutic strategies against HIV infection. -
CCR5 Antagonist
PF-232798 is an orally bioavailable antagonist of the CCR5 receptor, primarily known for its role in HIV entry into cells. By blocking CCR5, PF-232798 demonstrates efficacy in inhibiting HIV replication and offers potential applications in antiviral research. Its selective activity makes it a valuable tool for studying HIV pathogenesis and developing new therapeutic strategies against the virus. -
HIV Inhibitor
UK-88947 hydrochloride is a potent HIV protease inhibitor, primarily targeting HIV-1 replication. It effectively disrupts the early stages of the viral life cycle when administered to cells prior to infection. Additionally, UK-88947 hydrochloride inhibits viral protease activity during infection, thereby significantly impacting viral replication. This compound is valuable for research focused on developing therapeutic strategies against HIV. -
HIV Inhibitor
(D-Ala)-Peptide T is an octapeptide that acts as an HIV inhibitor by targeting the HIV-1 envelope glycoprotein gp120. This compound has been shown to release chemokines and protect against neuronal death induced by gp120. It is a valuable reagent for research into infectious diseases and neurological disorders, particularly AIDS-related dementia. -
Anti-HIV Agent
KP-1461 is a nucleoside derivative that acts as an anti-HIV agent by inducing lethal mutations in the viral genome. This compound has significant potential for research applications focused on HIV infection and the development of novel antiviral strategies. It is valuable for studies aimed at understanding the mechanisms of viral resistance and the efficacy of mutation-inducing therapies. -
HIV-1 Inhibitor
HIV-1 Inhibitor-29 is a potent inhibitor targeting the HIV-1 virus, demonstrating an EC50 of 2.18 μM against the HIV-1 IIIB strain. This compound exhibits significant anti-resistance properties against the F227L/V106A mutant strain, with an EC50 of 0.974 μM, while maintaining low cytotoxicity in MT-4 cells (CC50 = 211 μM). HIV-1 Inhibitor-29 is a valuable tool for research focused on AIDS and HIV-1 therapeutic development. -
Non-Nucleoside rReverse Transcriptase Inhibitor
UC-84 (NSC-615985) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that exhibits potent anti-HIV activity. By targeting the reverse transcriptase enzyme, UC-84 effectively disrupts viral replication, making it a valuable compound for HIV research. Its application extends to studies focused on the mechanisms of viral resistance and the development of novel therapeutic strategies against HIV. -
HIV-1 TAR RNA Binder
WRNA10 is a potent HIV-1 TAR RNA binder that exhibits an IC50 of 10 µM, demonstrating its efficacy in inhibiting interactions with the TAR RNA structure. With a CC50 value of 40 µM, WRNA10 serves as a valuable tool for studying HIV-1 RNA functionalities and therapeutic approaches targeting HIV-1 infections. Its precise binding affinity and biological activity make it suitable for research applications in virology and antiviral drug development. -
HIV-1 Inhibitor
NNRT-IN-1 is a potent non-nucleoside reverse transcriptase (NNRT) inhibitor targeting HIV-1. This compound demonstrates significant anti-resistance efficacy, effectively inhibiting wild-type HIV-1 as well as five mutant strains, with EC50 values in the nanomolar range. Additionally, NNRT-IN-1 exhibits favorable pharmacokinetic properties, making it a valuable tool for research applications in HIV therapeutics. -
HIV Inhibitor
(+)-Carbovir is a nucleoside analog specifically designed to inhibit human immunodeficiency virus type 1 (HIV-1). Its enhanced chemical and metabolic stability contributes to its antiviral efficacy. This compound serves as a valuable tool in AIDS research, facilitating studies aimed at understanding and combating HIV infection. -
HIV-1 RT Inhibitor
Tivirapine is a non-nucleoside inhibitor targeting HIV-1 reverse transcriptase (RT), demonstrating potent antiviral activity with an EC50 value of 4 nM. This compound effectively inhibits the Y181C mutant of HIV-1 RT, offering a valuable tool for studying drug resistance mechanisms and evaluating therapeutic strategies against HIV-1 infection. Its application is relevant in both basic research and development of novel antiviral therapies. -
HIV-1 Inhibitor
HIV-1 inhibitor-64 (Compound 7c) is a potent antagonist targeting HIV-1, demonstrating effective inhibition of both wild-type and resistant mutants, specifically E138K/Q148K and G140S/Q148R, with EC50 values of 62.5 nM and 11.3 nM, respectively. This compound exhibits significant antiviral activity, making it a valuable tool for AIDS research and studies focused on HIV-1 resistance mechanisms. -
HIV
(Threo)-Indinavir is a potent protease inhibitor targeting HIV-1, crucial for the management of HIV/AIDS. By obstructing the viral protease activity, (threo)-Indinavir effectively disrupts viral replication. This compound is commonly utilized as part of highly active antiretroviral therapy (HAART) for the suppression of HIV viral load in infected individuals.
